1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-5-fluoro-1-((4-fluorophenyl)methyl)-alpha-oxo- | 444659-44-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-5-fluoro-1-((4-fluorophenyl)methyl)-alpha-oxo-
• 英文别名: N-(3,5-dichloropyridin-4-yl)-2-[5-fluoro-1-[(4-fluorophenyl)methyl]indol-3-yl]-2-oxoacetamide
• CAS: 444659-44-3
• 化学式: C₂₂H₁₃Cl₂F₂N₃O₂
• 分子量: 460.3
• InChiKey: RELJWHOMJUFVIO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  64
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist
  申请人：Nycomed GmbH

  公开号：EP1849468A2

  公开（公告）日：2007-10-31

  The invention relates to the combined administration of PDE4 or PDE3/4 inhibitors and histamine receptor antagonists for the treatment of respiratory diseases.

  本发明涉及联合使用 PDE4 或 PDE3/4 抑制剂和组胺受体拮抗剂治疗呼吸系统疾病。
• USE OF PDE4 INHIBITORS FOR THE PROPHYLAXIS AND/OR THERAPY OF DYSLIPOPROTEINAEMIA AND RELATED DISORDERS
  申请人：Albert-Ludwigs-Universität Freiburg

  公开号：EP3165224A1

  公开（公告）日：2017-05-10

  The present invention discloses medical uses of phosphodiesterase 4 (PDE 4) inhibitors for treating dyslipoproteinaemia and of diseases when respectively correlated or associated with dyslipoproteinaemia or lipoprotein imbalance, in particular abnormally high low density lipoprotein (LDL) in blood or serum, such as endothelial dysfunction, cardiovascular diseases, in particular arteriosclerosis, myocardial infarction, stroke, peripheral artery disease, and vascular stenosis or restenosis, independent and distinct from inflammatory diseases or conditions such as inflammatory-associated cardiovascular pathology and cardiac hypertrophy. Accordingly the present invention allows reducing cardiovascular risks especially in circumstances of abnormal high LDL levels and especially LDL-cholesterol and LDL-triglyceride levels.

  本发明公开了磷酸二酯酶4 (PDE 4)抑制剂的医疗用途，用于治疗分别与脂蛋白血症或脂蛋白失衡，特别是血液或血清中异常高的低密度脂蛋白(LDL)有关或相关的脂蛋白血症和疾病、如内皮功能障碍、心血管疾病，特别是动脉硬化、心肌梗塞、中风、外周动脉疾病和血管狭窄或再狭窄，独立于炎症性疾病或病症，如炎症相关的心血管病变和心脏肥大。因此，本发明可以降低心血管风险，特别是在低密度脂蛋白水平异常高，尤其是低密度脂蛋白胆固醇和低密度脂蛋白甘油三酯水平异常高的情况下。
• Combination
  申请人：——

  公开号：US20030092706A1

  公开（公告）日：2003-05-15

  The invention relates to the combined administration of a PDE4 or PDE3/4 inhibitor and a disease modifying anti-rheumatic drug (DMARDs) or anti-rheumatic or anti-arthritic drug.

  本发明涉及 PDE4 或 PDE3/4 抑制剂与改变病情抗风湿药（DMARDs）或抗风湿或抗关节炎药物的联合用药。
• Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist
  申请人：Beume Rolf

  公开号：US20050112069A1

  公开（公告）日：2005-05-26

  The invention relates to the combined administration of PDE4 or PDE3/4 inhibitors and histamine receptor antagonists for the treatment of respiratory diseases.

  本发明涉及联合使用 PDE4 或 PDE3/4 抑制剂和组胺受体拮抗剂治疗呼吸系统疾病。
• Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
  申请人：Schmidt Mathias

  公开号：US20060079540A1

  公开（公告）日：2006-04-13

  The invention relates to the use of a PDE4 or PDE3/4 inhibitor for the treatment of cachexia.

  本发明涉及使用 PDE4 或 PDE3/4 抑制剂治疗恶病质。